Organogenesis Holdings Inc (OQ:ORGO)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 85 Dan Rd
CANTON MA 02021-2810
Tel: N/A
Website: https://investors.organogenesis.com
IR: See website
<
Key People
Gary S. Gillheeney
President, Chief Executive Officer, Director
David C. Francisco
Chief Financial Officer
Patrick Bilbo
Chief Operating Officer
Lori Freedman
Chief Administrative and Legal Officer
Antonio S. Montecalvo
Vice President - Health Policy
Brian Grow
Chief Commercial Officer
Business Overview
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.
Financial Overview
For the fiscal year ended 31 December 2023, Organogenesis Holdings Inc revenues decreased 4% to $433.1M. Net income decreased 68% to $4.9M. Revenues reflect Advanced Wound Care segment decrease of 4% to $405.5M, Surgical & Sports Medicine segment decrease of 4% to $27.6M. Net income also reflects Research and development increase of 12% to $44.4M (expense).
Employees: 862 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $342.77M as of Dec 31, 2023
Annual revenue (TTM): $433.14M as of Dec 31, 2023
EBITDA (TTM): $35.17M as of Dec 31, 2023
Net annual income (TTM): $4.95M as of Dec 31, 2023
Free cash flow (TTM): $6.55M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 131,963,176 as of Feb 26, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.